Rifaximin for Functional Dyspepsia

Functional dyspepsia is a very common medical condition, which occurs in up to 30% of people
in the community. However, results of current pharmacological treatment on functional
dyspepsia are unsatisfactory. Rifaximin is a minimally absorbed antibiotic that has been
used in treatment of non-constipated irritable bowel syndrome (IBS). In particular, bloating
and abdominal pain was improved by rifaximin treatment in this group of IBS patients. Whilst
there is considerable overlap in symptoms of functional dyspepsia and IBS, the investigators
test whether rifaximin is also effective in curing post-prandial distress symptoms related
to dyspepsia.

Clinical Trial Conditions: Functional Dyspepsia

Treatments in this Clinical Trial : Rifaximin, Placebo

Eligible Clinical Trial Participant Age : Between 18 years to 70 years

Can Healthy Volunteers Participate: No

Clinical Trial Lead Sponsor: The University of Hong Kong

Detailed Clinical Trial Description: Functional dyspepsia is a very common medical condition, which occurs in up to 30% of people
in the community. However, results of current pharmacological treatment on functional
dyspepsia are unsatisfactory. Rifaximin is a minimally absorbed antibiotic that has been
used in treatment of non-constipated irritable bowel syndrome (IBS). In particular, bloating
and abdominal pain was improved by rifaximin treatment in this group of IBS patients. Whilst
there is considerable overlap in symptoms of functional dyspepsia and IBS, the investigators
test whether rifaximin is also effective in curing post-prandial distress symptoms related
to dyspepsia.

The clinical trial information was obtained from http://clinicaltrials.gov/ct2/show/NCT01643083